Gemini Therapeutics Inc
Change company Symbol lookup
Select an option...
GMTX Gemini Therapeutics Inc
GSS Golden Star Resources Ltd
T AT&T Inc
TBNK Territorial Bancorp Inc
YUM Yum! Brands Inc
RTX Raytheon Technologies Corp
NAKD Naked Brand Group Ltd
FAMI Farmmi Inc
PTPI Petros Pharmaceuticals Inc
ZNGA Zynga Inc
Go

Health Care : Biotechnology |
Company profile

Gemini Therapeutics, Inc., formerly FS Development Corp., is a clinical-stage precision medicine company. The Company is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The Company's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH is a construct that express GEM103 continuously at a therapeutic level. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.

Closing Price
$2.39
Day's Change
-0.22 (-8.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.67
Day's Low
2.30
Volume
(Heavy Day)
Volume:
125,715

10-day average volume:
102,555
125,715
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.